Approval · Notice of Compliance 32815 · 2024
AZITHROMYCIN: Notice of Compliance 32815
Issued March 4, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32815
- Date
- March 4, 2024
- Company
- 10445517 Canada IncLaval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement Between Two Manufacturers
- Canadian reference product
- ZITHROMAX (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AZITHROMYCIN | 02545969 | Marketed |
| AZITHROMYCIN | 02545977 | Approved |
Medicinal ingredients
- AZITHROMYCIN 250 MG per TAB
- AZITHROMYCIN 600 MG per TAB